04-14-04

PATENT
Client-matter no.: 66784-015

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
Kees Jalink

Serial No.: 10/607,037

Filed: June 25, 2003

For: MEMBRANE MOLECULE INDICATOR COMPOSITIONS AND METHODS

Confirmation No.: 6398

Group Art Unit: Unassigned

Examiner: Unassigned

CERTIFICATE OF MAILING BY "EXPRESS MAIL"
"EXPRESS MAIL" MAILING LABEL NUMBER: EV 400 552 971 US
DATE OF DEPOSIT: APRIL 12, 2004

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VIRGINIA 22313-1450.

Leand Bantados
Printed Name of Person Mailing Paper or Fee

Signature of Person Mailing Paper or Fee

Mail Stop PGPUB
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

REQUEST FOR CORRECTED PATENT APPLICATION PUBLICATION

The Applicants respectfully request a corrected patent application publication under 37 C.F.R. § 1.221(b).

The Applicants believe that publication No. US-2004-0029206-A1, published February 12, 2004, contains the following material mistakes that are apparent from USPTO records:

1. Page 19, claim 9; please delete the "PLCβ1 or PLCβ1" and replace therefor with "PLCδ1 or PLCβ1". See attached page 76 of the original specification, which shows this to be a PTO error.

Accordingly, Applicants request that these errors be corrected in the USPTO's electronic copy of the Specification and that the USPTO publish a corrected patent application publication.

No fee is deemed necessary to file this Request. If any fee is required, authorization is hereby given to charge the amount to Deposit Account No. 502624. A duplicate copy of this sheet is enclosed for this purpose.

Respectfully submitted,

Date: April 12, 2004

David A. Gay
Registration No. 39,200
Telephone: (858) 535-9001
Facsimile: (858) 535-8949

McDERMOTT, WILL & EMERY
4370 La Jolla Village Drive, Suite 700
San Diego, California 92122

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 5

ggctgagacc cgggaattcg gcttgtacag ctcgtccatg 40

<210> SEQ ID NO 6
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 6

Lys Met Ser Lys Asp Gly Lys Lys Lys Lys Lys Lys Ser Lys Thr Lys
1 5 10 15

Cys Val Ile Met
20

<210> SEQ ID NO 7
<211> LENGTH: 39
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 7

ccgaattccc gggtcaagat gagcaaagat ggtaaaaag 39

<210> SEQ ID NO 8
<211> LENGTH: 42
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer

<400> SEQUENCE: 8

cctgcggccg cggtaccgag atctttacat aattacacac tt 42

What is claimed is:

1. A phosphatidylinositol 4,5-bisphosphate (PIP2) indicator, said indicator comprising:

(a) a first polypeptide comprising:

(i) a pleckstrin homology (PH) domain; and

(ii) a donor fluorescent domain

(b) a second polypeptide comprising:

(i) a pleckstrin homology (PH) domain; and

(ii) an acceptor fluorescent domain;

wherein fluorescence resonance energy transfer (FRET) between said donor domain and said acceptor domain indicates PIP2 levels.

2. The indicator of claim 1, wherein said PH domain is a PLCδ1 or PLCβ PH domain.

3. The indicator of claim 1, wherein said donor fluorescent domain is selected from the group consisting of a GFP and a dsRED.

4. The indicator of claim 1, wherein said donor fluorescent domain is a CFP.

5. The indicator of claim 1, wherein said acceptor fluorescent domain is selected from the group consisting of a GFP and a dsRED.

6. The indicator of claim 1, wherein said acceptor fluorescent domain is a YFP.

7. A cell comprising the indicator of claim 1.

8. A nucleic acid kit, the nucleic acid molecule components of which encode a PIP2 indicator, said indicator comprising:

(a) a first polypeptide comprising:

(i) a PH domain; and

(ii) a donor fluorescent domain

(b) a second polypeptide comprising:

(i) a PH domain; and

(ii) an acceptor fluorescent domain;

wherein fluorescence resonance energy transfer (FRET) between said donor domain and said acceptor domain indicates PIP2 levels.

9. The kit of claim 8, wherein said PH domain is a PLCβ1 or PLCβ PH domain.

8. A nucleic acid kit, the nucleic acid molecule components of which encode a PIP2 indicator, said indicator comprising:

(a) a first polypeptide comprising:

(i) a PH domain; and

(ii) a donor fluorescent domain

(b) a second polypeptide comprising:

(i) a PH domain; and

(ii) an acceptor fluorescent domain;

wherein fluorescence resonance energy transfer (FRET) between said donor domain and said acceptor domain indicates PIP2 levels.

9. The kit of claim 8, wherein said PH domain is a PLCδ1 or PLCβ PH domain.

10. The kit of claim 8, wherein said donor fluorescent domain is selected from the group consisting of a GFP and a dsRED.

11. The kit of claim 8, wherein said donor fluorescent domain is a CFP.

12. The kit of claim 8, wherein said acceptor fluorescent domain is selected from the group consisting of a GFP and a dsRED.

13. The kit of claim 8, wherein said acceptor fluorescent domain is a YFP.

14. A cell expressing the nucleic acid molecule components of the kit of claim 8.